Cost-benefit analysis favours use of HbA1c for diabetes diagnosis

A submission was made by the Royal College of Pathologists of Australasia (RCPA) and the Australian Diabetes Society at the end of 2011 to seek a rebate for glycated haemoglobin testing.

In a position statement published in the Medical Journal of Australia, the two groups, together with the Australasian Association of Clinical Biochemists, stated that measuring blood glucose levels was associated with methodological, procedural and practical problems such as day-to-day variation of levels, variations between laboratories and ex-vivo inaccuracy.